Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Stoke Therapeutics Inc.

    NASDAQ: STOK · Real-Time Price · USD
    8.75
    -0.95 (-9.79%)
    At close: May 06, 2025, 3:59 PM
    8.75
    0.00%
    After-hours: May 06, 2025, 04:05 PM EDT
    -9.79%
    Bid 6.84
    Market Cap 477.72M
    Revenue (ttm) 36.55M
    Net Income (ttm) -88.98M
    EPS (ttm) -1.65
    PE Ratio (ttm) -5.3
    Forward PE -3.92
    Analyst Buy
    Ask 10.75
    Volume 1,093,283
    Avg. Volume (20D) 861,760
    Open 9.50
    Previous Close 9.70
    Day's Range 8.30 - 9.53
    52-Week Range 5.35 - 17.58
    Beta 1.20

    About STOK

    Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome,...

    [Read more]
    Industry Biotechnology
    Sector Healthcare
    IPO Date Jun 19, 2019
    Employees 128
    Stock Exchange NASDAQ
    Ticker Symbol STOK
    Website https://www.stoketherapeutics.com
    Full Company Profile

    Analyst Forecast

    According to 6 analyst ratings, the average rating for STOK stock is "Buy." The 12-month stock price forecast is $21, which is an increase of 140.00% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Stoke Therapeutics Inc. is scheduled to release its earnings on May 20, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    5 months ago
    +12.07%
    Stoke Therapeutics shares are trading higher after... Unlock content with Pro Subscription
    6 months ago
    +1.53%
    Stoke Therapeutics shares are trading higher on possible continued strength following Q3 reported financial results yesterday. Also, Needham and HC Wainwright & Co. reiterated Buy ratings on the stock.
    news image

    1 week ago · zacks.com

    Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

    Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    2 weeks ago · zacks.com

    Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?

    Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    2 weeks ago · zacks.com

    Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?

    Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d...

    news image

    1 month ago · businesswire.com

    Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

    BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...

    news image

    1 month ago · investopedia.com

    Stoke Therapeutics Stock Slips as CEO Steps Down

    Shares of Stoke Therapeutics (STOK) slipped Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.

    news image

    1 month ago · zacks.com

    Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates

    Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.60 per share a year ago.

    news image

    1 month ago · businesswire.com

    Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

    BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...

    news image

    1 month ago · businesswire.com

    Stoke Therapeutics Announces CEO Transition

    BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...

    news image

    1 month ago · zacks.com

    Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    2 months ago · businesswire.com

    Stoke Therapeutics to Present at Upcoming Investor Conferences in March

    BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today ...

    Add to Watchlist